Principal Financial Group
VNDA icon

Principal Financial Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Principal Financial Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,774
Closed -$130K – 2500
2023
Q4 		$130K Buy
30,774
+5,310
+21% +$21.4K ﹤0.01% 2231
2023
Q3 		$110K Sell
25,464
-311,998
-92% -$1.73M ﹤0.01% 2270
2023
Q2 		$2.22M Sell
337,462
-13,306
-4% -$85.3K ﹤0.01% 1750
2023
Q1 		$2.38M Sell
350,768
-4,907
-1% -$34.5K ﹤0.01% 1729
2022
Q4 		$2.63M Sell
355,675
-6,110
-2% -$59.5K ﹤0.01% 1713
2022
Q3 		$3.58M Sell
361,785
-23,933
-6% -$253K ﹤0.01% 1602
2022
Q2 		$4.21M Sell
385,718
-14,806
-4% -$153K ﹤0.01% 1615
2022
Q1 		$4.53M Sell
400,524
-20,099
-5% -$264K ﹤0.01% 1692
2021
Q4 		$6.6M Sell
420,623
-24,933
-6% -$434K ﹤0.01% 1571
2021
Q3 		$7.64M Sell
445,556
-5,236
-1% -$91.7K 0.01% 1522
2021
Q2 		$9.7M Sell
450,792
-469
-0.1% -$8.39K 0.01% 1446
2021
Q1 		$6.78M Buy
451,261
+6,640
+1% +$107K ﹤0.01% 1557
2020
Q4 		$5.84M Buy
444,621
+49,989
+13% +$602K ﹤0.01% 1504
2020
Q3 		$3.81M Sell
394,632
-14,225
-3% -$152K ﹤0.01% 1561
2020
Q2 		$4.68M Sell
408,857
-4,118
-1% -$46.6K ﹤0.01% 1454
2020
Q1 		$4.28M Sell
412,975
-16,193
-4% -$201K ﹤0.01% 1341
2019
Q4 		$7.04M Buy
429,168
+8,980
+2% +$136K 0.01% 1412
2019
Q3 		$5.58M Sell
420,188
-4,591
-1% -$64K ﹤0.01% 1476
2019
Q2 		$5.99M Sell
424,779
-6,262
-1% -$99.7K 0.01% 1470
2019
Q1 		$7.93M Sell
431,041
-2,299
-0.5% -$52.4K 0.01% 1365
2018
Q4 		$11.3M Sell
433,340
-7,909
-2% -$186K 0.01% 1097
2018
Q3 		$10.1M Buy
+441,249
New +$9.01M 0.01% 1315
2017
Q4 		– Sell
-213,898
Closed -$3.83M – 2274
2017
Q3 		$3.83M Buy
213,898
+1,500
+0.7% +$25.1K ﹤0.01% 1629
2017
Q2 		$3.46M Buy
212,398
+123
+0.1% +$1.77K ﹤0.01% 1649
2017
Q1 		$2.97M Sell
212,275
-3,000
-1% -$42.8K ﹤0.01% 1670
2016
Q4 		$3.43M Buy
215,275
+10,426
+5% +$168K ﹤0.01% 1629
2016
Q3 		$3.41M Buy
204,849
+1,249
+0.6% +$16.8K ﹤0.01% 1588
2016
Q2 		$2.28M Sell
203,600
-4,900
-2% -$47.5K ﹤0.01% 1631
2016
Q1 		$1.74M Hold
208,500
– – ﹤0.01% 1658
2015
Q4 		$1.94M Hold
208,500
– – ﹤0.01% 1656
2015
Q3 		$2.35M Buy
208,500
+2,200
+1% +$26.9K ﹤0.01% 1603
2015
Q2 		$2.62M Buy
206,300
+4,665
+2% +$50.3K ﹤0.01% 1628
2015
Q1 		$1.88M Buy
201,635
+13,135
+7% +$148K ﹤0.01% 1670
2014
Q4 		$2.7M Sell
188,500
-8,513
-4% -$101K ﹤0.01% 1614
2014
Q3 		$2.04M Sell
197,013
-3,540
-2% -$46.4K ﹤0.01% 1646
2014
Q2 		$3.25M Buy
200,553
+11,353
+6% +$151K 0.01% 1583
2014
Q1 		$3.08M Sell
189,200
-15,985
-8% -$227K 0.01% 1565
2013
Q4 		$2.55M Buy
205,185
+89,200
+77% +$896K ﹤0.01% 1620
2013
Q3 		$1.27M Buy
115,985
+101,246
+687% +$1.08M ﹤0.01% 1715
2013
Q2 		$119K Buy
+14,739
New +$99.3K ﹤0.01% 2184

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Financial Group's VNDA Position: Q1 2024 in Review

Principal Financial Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 30,774 shares — an estimated $130K sold.

Principal Financial Group first reported a position in VNDA in Q2 2013 and held it in 40 quarters. The position peaked at $11.3M in Q4 2018. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Principal Financial Group reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Principal Financial Group sold 30,774 Vanda Pharmaceuticals shares in Q1 2024, an estimated $130K.
  • Principal Financial Group first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 40 quarters.
  • Principal Financial Group's Vanda Pharmaceuticals position peaked at $11.3M in Q4 2018.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Principal Financial Group's 13F filing for Q1 2024, filed 29 Apr 2024.